Blog - Latest News

You are here: Home » General Biotechnology » Why Merck Missed the Mark
October 24, 2003
24 Oct 2003

Why Merck Missed the Mark

Why Merck Missed the Mark
S&P’s Herman Saftlas talks about the Street’s reaction to the drug giant’s disappointing earnings report and what the future may hold

0 Comments/0 Tweets/in General Biotechnology
0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Get updates by email


 

BiotechBlog’s Editor

Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.

Read More...

Network and Share

Connect on LinkedIn
Join BiotechBlog on LinkedIn
Follow BiotechBlog on Twitter
Share BiotechBlog on LinkedIn  Tweet BiotechBlog on Twitter Email biotechnology policy, regulation, and law

Categories

Recommended Reading

Image of Great Patents: Advanced Strategies For Innovative Growth Companies
Image of Get to Market Now! Turn FDA Compliance into a Competitive Edge in the Era of Personalized Medicine
Image of Building the Case for Biotechnology: Management Case Studies in Science, Laws, Regulations, Politics, and Business
Image of Biotechnology Entrepreneurship From Science to Solutions -- Start-up, Company Formation and Organization, Team, Intellectual Property, Financing, ... Regulatory Affairs, Reimbursement, Exit
Image of Biotechnology Entrepreneurship Bootcamp: Journal of Commercial Biotechnology Special Issue
Image of The Life Science Innovation Roadmap: Bioscience Innovation Assessment, Planning, Strategy, Execution, and Implementation
Image of Revolutions: Paving the Way for the Bioeconomy
Image of Building Biotechnology: Business, Regulations, Patents, Law, Politics, Science

Translator

© Copyright - BiotechBlog — A thinkBiotech product